Key facts
- Ruipuchenchuang’s last known valuation is $300.4M (Nov 2024).
- It has raised $84.3M; the latest was Later Stage VC ($70.3M) in Nov 2025.
- Notable investors include Lenovo Capital and Incubator Group, YuanBio Venture Capital, Hangzhou Dongfang Jiafu Asset Management, Lotus Lake Ventures, Jiangsu Huarui Investment — 12 tracked in total.
- Status: Privately Held (backing).
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ruipuchenchuang
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruipuchenchuang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruipuchenchuang
Developer of advanced biomedical solutions designed for regenerative stem cell medicine. The company offers pioneering stem cell therapies using proprietary human pluripotent stem cell technology, cell differentiation processes, clinical-grade manufacturing, and preclinical safety evaluation, thereby enabling innovative treatment options in the field of regenerative medicine.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Employees
- 19
- Website
- reprogenix.com/
- Ownership
- Privately Held (backing)
Ruipuchenchuang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruipuchenchuang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruipuchenchuang in its N-PORT filings yet. We sweep new filings monthly.